The need in Africa is large, but economics are difficult.
" The first malaria vaccine, Mosquirix from British drugmaker GSK (GSK.L), was endorsed by the WHO last year after decades of work. But a lack of funding and commercial potential is thwarting GSK’s capacity to produce as many doses as needed, demonstrating the need for another candidate."